In short
Defactinib, also known as VS-6063, is an investigational drug being studied in clinical trials for its potential to treat various types of cancer. As a focal adhesion kinase (FAK) inhibitor, defactinib targets a protein involved in cancer cell growth and survival. This article summarizes key information about ongoing clinical trials evaluating defactinib alone or in combination with other therapies for conditions including ovarian cancer, lung cancer, mesothelioma, and other advanced solid tumors.
At a glance
- Drug Name
- Defactinib (VS-6063)
- Drug Class
- Focal Adhesion Kinase (FAK) Inhibitor
- Administration
- Oral, typically twice daily
- Cancer Types Studied
- Ovarian, Non-Small Cell Lung Cancer, Mesothelioma, Advanced Solid Tumors
- Combination Therapies
- Paclitaxel, Pembrolizumab, Avutometinib
- Key Outcomes Measured
- Safety, Tolerability, Pharmacokinetics, Tumor Response, Progression-Free Survival
- Notable Trial Designs
- Dose Escalation, Expansion Cohorts, Biomarker Analysis
What is Defactinib?
Defactinib, also known as VS-6063 or PF-04554878, is an investigational drug being studied for the treatment of various types of cancer. It is taken orally, usually in the form of tablets. Defactinib is not yet approved by the U.S. Food and Drug Administration (FDA) for general use, but it is being tested in clinical trials to determine its effectiveness and safety.
How Defactinib Works
Defactinib is a type of drug called a focal adhesion kinase (FAK) inhibitor. FAK is a protein that plays a role in cancer cell growth and survival. By blocking FAK, defactinib may help to slow down or stop the growth of cancer cells.
Research suggests that defactinib may also have effects on the immune system. It might help to change the environment around tumors, making it easier for the body's immune system to fight cancer cells.
Cancers Treated with Defactinib
Defactinib is being studied in several types of cancer, including:
- Non-small cell lung cancer (NSCLC): This is a common type of lung cancer.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Mesothelioma: A rare cancer that affects the lining of the lungs, chest wall, or abdomen.
- Pancreatic cancer: A cancer that starts in the pancreas.
- Thyroid cancer: Including both differentiated thyroid cancer and anaplastic thyroid cancer.
Clinical Trials and Research
Defactinib is currently being studied in various clinical trials. These trials are designed to test how well the drug works, what dose is best, and how safe it is. Some key areas of research include:
- Testing defactinib in combination with other cancer drugs.
- Studying how the body absorbs and processes defactinib.
- Investigating defactinib's effects in specific types of cancer, such as KRAS mutant non-small cell lung cancer.
- Exploring defactinib's potential in cancers with certain genetic changes, like NF2 mutations.
Combination Therapies
Researchers are particularly interested in how defactinib works when combined with other cancer treatments. Some combinations being studied include:
- Defactinib with pembrolizumab (a type of immunotherapy).
- Defactinib with paclitaxel (a chemotherapy drug).
- Defactinib with avutometinib (another targeted therapy).
These combinations are being tested to see if they can improve the effectiveness of cancer treatment compared to using single drugs alone.
Side Effects and Safety
As with all medications, defactinib can cause side effects. The full range of side effects is still being studied in clinical trials. Common side effects observed in studies include:
- Nausea
- Fatigue
- Diarrhea
- Vomiting
More serious side effects may also occur. In clinical trials, doctors closely monitor patients for any unexpected or severe side effects. It's important to note that the safety profile of defactinib is still being established through ongoing research.
If you're considering participating in a clinical trial involving defactinib, it's crucial to discuss potential risks and benefits with your healthcare team. They can provide the most up-to-date information about the drug and help you make an informed decision about your treatment options.